AR033978A1 - Molecula de anticuerpo con especificidad para factor de necrosis tumoral alfa humano y usos de las mismas - Google Patents

Molecula de anticuerpo con especificidad para factor de necrosis tumoral alfa humano y usos de las mismas

Info

Publication number
AR033978A1
AR033978A1 ARP010102689A ARP010102689A AR033978A1 AR 033978 A1 AR033978 A1 AR 033978A1 AR P010102689 A ARP010102689 A AR P010102689A AR P010102689 A ARP010102689 A AR P010102689A AR 033978 A1 AR033978 A1 AR 033978A1
Authority
AR
Argentina
Prior art keywords
antibody
antibody molecules
specificity
molecula
same
Prior art date
Application number
ARP010102689A
Other languages
English (en)
Spanish (es)
Inventor
Andrew George Popplewell
Andrew Paul Chapman
David John King
Diljeet Singh Athwal
Derek Thomas Brown
Andrew Neil Charles Weir
Original Assignee
Celltech Chiroscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9893121&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR033978(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celltech Chiroscience Ltd filed Critical Celltech Chiroscience Ltd
Publication of AR033978A1 publication Critical patent/AR033978A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compression Of Band Width Or Redundancy In Fax (AREA)
ARP010102689A 2000-06-06 2001-06-06 Molecula de anticuerpo con especificidad para factor de necrosis tumoral alfa humano y usos de las mismas AR033978A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0013810.7A GB0013810D0 (en) 2000-06-06 2000-06-06 Biological products

Publications (1)

Publication Number Publication Date
AR033978A1 true AR033978A1 (es) 2004-01-21

Family

ID=9893121

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010102689A AR033978A1 (es) 2000-06-06 2001-06-06 Molecula de anticuerpo con especificidad para factor de necrosis tumoral alfa humano y usos de las mismas

Country Status (42)

Country Link
US (4) US7012135B2 (cg-RX-API-DMAC7.html)
EP (4) EP2230308B1 (cg-RX-API-DMAC7.html)
JP (3) JP4064812B2 (cg-RX-API-DMAC7.html)
KR (1) KR20020047097A (cg-RX-API-DMAC7.html)
CN (1) CN1289671C (cg-RX-API-DMAC7.html)
AP (1) AP2092A (cg-RX-API-DMAC7.html)
AR (1) AR033978A1 (cg-RX-API-DMAC7.html)
AT (1) ATE451460T1 (cg-RX-API-DMAC7.html)
AU (1) AU783756B2 (cg-RX-API-DMAC7.html)
BE (1) BE2010C019I2 (cg-RX-API-DMAC7.html)
BG (1) BG66072B1 (cg-RX-API-DMAC7.html)
BR (2) BR0106682A (cg-RX-API-DMAC7.html)
CA (2) CA2707766C (cg-RX-API-DMAC7.html)
CY (6) CY1109889T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ300737B6 (cg-RX-API-DMAC7.html)
DE (3) DE122010000027I1 (cg-RX-API-DMAC7.html)
DK (4) DK2308975T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP024210A (cg-RX-API-DMAC7.html)
ES (5) ES2403217T3 (cg-RX-API-DMAC7.html)
FR (1) FR10C0015I2 (cg-RX-API-DMAC7.html)
GB (2) GB0013810D0 (cg-RX-API-DMAC7.html)
HU (4) HU230553B1 (cg-RX-API-DMAC7.html)
IL (3) IL147992A0 (cg-RX-API-DMAC7.html)
IS (2) IS2808B (cg-RX-API-DMAC7.html)
LT (1) LT2308975T (cg-RX-API-DMAC7.html)
LU (1) LU91674I2 (cg-RX-API-DMAC7.html)
MX (1) MXPA01013440A (cg-RX-API-DMAC7.html)
MY (1) MY136603A (cg-RX-API-DMAC7.html)
NL (1) NL300982I9 (cg-RX-API-DMAC7.html)
NO (4) NO334808B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ516596A (cg-RX-API-DMAC7.html)
OA (1) OA12282A (cg-RX-API-DMAC7.html)
PE (1) PE20020292A1 (cg-RX-API-DMAC7.html)
PL (2) PL218516B1 (cg-RX-API-DMAC7.html)
PT (4) PT3059314T (cg-RX-API-DMAC7.html)
RU (1) RU2303604C2 (cg-RX-API-DMAC7.html)
SI (3) SI1287140T1 (cg-RX-API-DMAC7.html)
SK (1) SK288343B6 (cg-RX-API-DMAC7.html)
TR (1) TR201900227T4 (cg-RX-API-DMAC7.html)
TW (2) TWI316088B (cg-RX-API-DMAC7.html)
WO (1) WO2001094585A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200200097B (cg-RX-API-DMAC7.html)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
GB0129105D0 (en) * 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
ES2358505T3 (es) * 2002-03-20 2011-05-11 Ucb Pharma, S.A. Métodos para analizar isómeros de disulfuro de anticuerpos.
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
BR122019027974B1 (pt) 2002-05-02 2022-06-14 Wyeth Holdings Corporation Composição compreendendo conjugado monomérico de derivado de caliqueamicina/anticorpo anti-cd22 e seu uso
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
US7601817B2 (en) 2002-05-28 2009-10-13 Ucb Pharma S.A. Antibody peg positional isomers, compositions comprising same, and use thereof
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
CA2493067A1 (en) * 2002-07-19 2004-01-29 Abbott Biotechnology Ltd. Treatment of tnf.alpha. related disorders
AU2003276844A1 (en) * 2002-08-28 2004-03-19 Pharmacia Corporation Formulations of modified antibodies and methods of making the same
AU2003265361A1 (en) * 2002-08-28 2004-03-19 Pharmacia Corporation Stable ph optimized formulation of a modified antibody
US20040105858A1 (en) * 2002-08-29 2004-06-03 Kim Joanne Young Hee Kwak Diagnosis and treatment of infertility
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
EP2311867A1 (en) 2002-10-29 2011-04-20 Anaphore, Inc. Trimeric binding proteins for trimeric cytokines
US7285269B2 (en) 2002-12-02 2007-10-23 Amgen Fremont, Inc. Antibodies directed to tumor necrosis factor
US7101978B2 (en) 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
WO2004065417A2 (en) * 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
GB0303337D0 (en) * 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
MXPA05008785A (es) * 2003-02-19 2005-10-18 Pharmacia Corp Esteres de polietilen glicol activados.
WO2004098578A2 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517
AU2004220325B2 (en) * 2003-06-30 2011-05-12 Domantis Limited Polypeptides
WO2005014649A2 (en) * 2003-08-08 2005-02-17 Pharmacia Corporation Method for the preparation of molecules having antibody activity
JP2007501622A (ja) * 2003-08-13 2007-02-01 サンド・アクチエンゲゼルシヤフト 組換えポリペプチドを精製するための方法
US7785830B2 (en) * 2003-08-13 2010-08-31 Sandoz Ag Expression vectors, transformed host cells and fermentation process for the production of recombinant polypeptides
GB0319601D0 (en) * 2003-08-20 2003-09-24 Sandoz Ag Production process
KR100570422B1 (ko) * 2003-10-16 2006-04-11 한미약품 주식회사 대장균 분비서열을 이용하여 항체 단편을 분비·생산하는 발현벡터 및 이를 이용하여 항체 단편을 대량 생산하는 방법
CN100393748C (zh) * 2003-11-06 2008-06-11 上海中信国健药业有限公司 全人源肿瘤坏死因子抗体，其制备方法以及药物组合物
KR100772800B1 (ko) * 2003-11-17 2007-11-01 주식회사유한양행 인간 종양괴사인자 α를 인식하는 단일클론항체의가변영역 및 이를 코딩하는 유전자
US7435799B2 (en) 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
CN100427504C (zh) * 2004-06-02 2008-10-22 北京天广实生物技术有限公司 TNFα高亲和力嵌合抗体及其用途
JP2008504356A (ja) * 2004-06-30 2008-02-14 ドマンティス リミテッド 炎症性疾患を治療するための組成物及び方法
GB0425972D0 (en) * 2004-11-25 2004-12-29 Celltech R&D Ltd Biological products
WO2006062776A2 (en) * 2004-11-29 2006-06-15 The Regents Of The University Of California Hydroxyapatite-binding peptides for bone growth and inhibition
CN101111521B (zh) * 2004-12-29 2011-08-24 株式会社柳韩洋行 肿瘤坏死因子-α特异性人源化抗体
JP5757495B2 (ja) 2005-05-16 2015-07-29 アッヴィ バイオテクノロジー リミテッド びらん性多発性関節炎の治療のためのｔｎｆ阻害剤の使用
NZ563213A (en) * 2005-06-01 2009-07-31 Micromet Ag Anti-IL2 antibodies
PL2390267T3 (pl) 2005-06-07 2013-09-30 Esbatech A Novartis Co Llc Stabilne i rozpuszczalne przeciwciała hamujące TNF(alfa)
GB0520169D0 (en) * 2005-10-04 2005-11-09 Celltech R&D Ltd Biological products
US9101670B2 (en) 2006-04-07 2015-08-11 Nektar Therapeutics Conjugates of an anti-TNF-α antibody
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
EP2666472A3 (en) * 2006-04-10 2014-04-02 Abbott Biotechnology Ltd Uses and compositions for treatment of psoriatic arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
JP5385135B2 (ja) 2006-07-03 2014-01-08 チャールズ デイビッド アデア， 細胞接着分子の発現を調節するための組成物
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
WO2008109462A2 (en) * 2007-03-02 2008-09-12 Farnam Companies, Inc. Sustained release pellets comprising wax-like material
EP2166844A4 (en) * 2007-06-07 2013-09-04 Evonik Corp DOSAGE FORMS WITH EXTENDED ACTION AND REDUCED MASS
WO2008154543A2 (en) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis
US8865875B2 (en) 2007-08-22 2014-10-21 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
CA2712965A1 (en) * 2008-02-05 2009-08-13 Delenex Therapeutics Ag Antigen-binding polypeptides against cartilage degeneration
JP5766598B2 (ja) * 2008-05-07 2015-08-19 アーゴス セラピューティクス インコーポレイテッド ヒトインターフェロン−αに対するヒト化抗体
AU2009264564B2 (en) 2008-06-25 2014-05-08 Novartis Ag Stable and soluble antibodies inhibiting TNFalpha
MX2011000052A (es) 2008-06-25 2011-07-29 Esbatech Alcon Biomed Res Unit Humanizacion de anticuerpos de conejos usando una estructura de anticuerpos universal.
SI2752428T1 (sl) 2008-06-25 2020-03-31 Novartis Ag Humaniziranje zajčjih protiteles z uporabo univerzalnega ogrodja protitelesa
LT3216803T (lt) 2008-06-25 2020-06-10 Novartis Ag Stabilūs ir tirpūs antikūnai, slopinantys vegf
CN101684156B (zh) * 2008-09-27 2011-12-28 苏州工业园区晨健抗体组药物开发有限公司 人TNFα单克隆抗体、其PEG化纳米颗粒及其应用
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
EP2391652A4 (en) * 2009-01-29 2013-01-02 Abbott Lab IL-1 BINDING PROTEINS
DK2451839T3 (da) 2009-07-10 2020-07-13 Ablynx Nv Fremgangsmåde til produktion af variable domæner
CA2774692C (en) 2009-09-24 2017-12-19 Ucb Pharma S.A. Bacterial strain for recombinant protein expression, having protease deficient degp retaining chaperone activity, and knocked out tsp and ptr genes
MY173390A (en) 2009-10-23 2020-01-22 Takeda Pharmaceuticals Co Anti-gcc antibody molecules and related compositions and methods
GB201000588D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000587D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000591D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000590D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201001791D0 (en) 2010-02-03 2010-03-24 Ucb Pharma Sa Process for obtaining antibodies
BR112012022342A2 (pt) 2010-03-04 2017-02-14 Vet Therapeutics Inc anticorpos monoclonais dirigidos a cd52
US9616120B2 (en) 2010-03-04 2017-04-11 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD20
JP2013523153A (ja) 2010-04-07 2013-06-17 アッヴィ・インコーポレイテッド ＴＮＦ−α結合タンパク質
GB201012599D0 (en) * 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
GB201012603D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Protein purification
GB201012784D0 (en) * 2010-07-29 2010-09-15 Ucb Pharma Sa Method
TWI538918B (zh) 2010-10-20 2016-06-21 財團法人工業技術研究院 人源化之單株抗體、其核苷酸序列與其用途
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
CA2837634C (en) 2011-06-01 2021-12-14 Actogenix Nv Polycistronic expression system for bacteria
EP2546267A1 (en) 2011-07-13 2013-01-16 UCB Pharma S.A. Bacterial host strain expressing recombinant DsbC
LT2731973T (lt) 2011-07-13 2018-02-26 Ucb Biopharma Sprl Bakterijų padermė, ekspresuojanti rekombinantinį dsbc
ES2676707T3 (es) 2011-09-23 2018-07-24 Intrexon Actobiotics Nv Bacterias gram positivas modificadas y usos de las mismas
RU2653757C2 (ru) 2011-09-23 2018-05-14 Интрексон Актобиотикс Н.В. Модифицированные грамположительные бактерии и их применение
EP2791169B1 (en) 2011-12-16 2017-07-19 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
GB201208367D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
US10113002B2 (en) 2012-08-13 2018-10-30 Genentech, Inc. Anti-jagged antibodies and methods of use
JP2017518737A (ja) 2014-04-21 2017-07-13 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ＳＹＫ標的治療薬のための抗ｐＳＹＫ抗体分子及びその使用
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
ES3046837T3 (en) 2014-12-22 2025-12-02 UCB Biopharma SRL Method of protein manufacture
US11091559B2 (en) 2015-08-27 2021-08-17 Celldex Therapeutics, Inc. Anti-ALK antibodies and methods for use thereof
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
WO2017122180A1 (en) 2016-01-14 2017-07-20 Intrexon Actobiotics N.V. Compositions and methods for the treatment of type 1 diabetes
RU2680011C2 (ru) * 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
AU2017274442B2 (en) * 2016-06-02 2021-08-19 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
PT3658192T (pt) 2017-12-01 2021-06-25 Abbvie Inc Agonista recetor de glucocorticóide e imunoconjugados do mesmo
US12503505B2 (en) 2019-01-31 2025-12-23 Numab Therapeutics AG Multispecific antibodies having specificity for TNFα and IL-17A, antibodies targeting IL-17A, and methods of use thereof
KR102323342B1 (ko) * 2019-04-26 2021-11-08 주식회사 와이바이오로직스 IL-17A 및 TNF-α에 특이적으로 결합하는 이중표적 항체
CN111909268B (zh) * 2019-05-07 2022-04-19 北京天成新脉生物技术有限公司 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用
TW202237638A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
TW202237639A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
IL305181A (en) 2021-02-15 2023-10-01 Takeda Pharmaceuticals Co Cell therapy compositions and methods for modulating tgf-b signaling
US20250002527A1 (en) 2021-08-26 2025-01-02 Duality Biologics (Suzhou) Co., Ltd. Steroid compound and conjugate thereof
SE545714C2 (en) * 2021-09-24 2023-12-19 Xbrane Biopharma Ab Dna contructs for producing a pelb signal peptide
SE545694C2 (en) * 2021-09-24 2023-12-05 Xbrane Biopharma Ab Dna construct comprising nucleotide sequences encoding amino acid sequences of certolizumab and pelb signal peptides
WO2023046930A1 (en) 2021-09-24 2023-03-30 Xbrane Biopharma Ab Dna constructs and host cells for expressing recombinant protein
WO2023154799A1 (en) 2022-02-14 2023-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination immunotherapy for treating cancer
JP2025534350A (ja) 2022-09-30 2025-10-15 エクステンド バイオサイエンシズ インコーポレーテッド 長時間作用型副甲状腺ホルモン
WO2024180518A1 (en) * 2023-03-01 2024-09-06 Lupin Limited Process for manufacturing antibody fragment protein
TW202525846A (zh) 2023-08-25 2025-07-01 美商普羅特歐拉吉克適美國公司 抗ｉｌ—１３多特異性抗體構築體及其用途
WO2025099576A1 (en) 2023-11-06 2025-05-15 Momenta Pharmaceuticals, Inc. Compositions and methods for treating rheumatoid arthritis

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
US5030570A (en) 1988-06-30 1991-07-09 The Eunice Kennedy Shriver Center For Mental Retardation DNA encoding and method of expressing human monoamine oxidase type A
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
PT92900A (pt) * 1989-01-24 1990-07-31 Sistema de vectores de expressao para a producao de anticorpos monoclonais quimericos
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
DE69420137T2 (de) * 1993-06-03 1999-12-23 Therapeutic Antibodies, Inc. Herstellung von antikörperfragmenten
NO309690B1 (no) 1995-01-23 2001-03-12 Western Atlas Int Inc Detonasjonsanordning av type eksploderende brotråd for bruk med et perforeringsverktöy i en brönn
EP0871641A4 (en) 1995-04-20 2001-09-26 Kennedy Inst Of Rheumatology MULTIPLE ADMINISTRATION OF ANTI-TNF ANTIBODIES
BRPI9707379B8 (pt) 1996-02-09 2015-07-07 Abbvie Biotechnology Ltd Composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado.
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) * 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
AU9262598A (en) * 1997-08-18 1999-03-08 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
GB9720054D0 (en) * 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
EP1061954B1 (en) 1998-03-12 2004-06-09 Nektar Therapeutics Al, Corporation Poly(ethylene glycol) derivatives with proximal reactive groups
GB9812545D0 (en) * 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products

Also Published As

Publication number Publication date
CY2010011I1 (el) 2012-01-25
AU6051101A (en) 2001-12-17
BG106278A (bg) 2002-12-29
TWI316088B (en) 2009-10-21
IL147992A0 (en) 2002-09-12
DE122010000027I1 (de) 2010-08-12
EP2230308A1 (en) 2010-09-22
US7012135B2 (en) 2006-03-14
ES2403217T3 (es) 2013-05-16
US20030026805A1 (en) 2003-02-06
EP3059314B1 (en) 2018-10-24
US7977464B2 (en) 2011-07-12
PL353960A1 (en) 2003-12-15
HU230669B1 (hu) 2017-07-28
BR0106682A (pt) 2002-05-14
PE20020292A1 (es) 2002-05-08
MXPA01013440A (es) 2003-09-04
BE2010C019I2 (cg-RX-API-DMAC7.html) 2020-08-20
NO20020554D0 (no) 2002-02-04
ES2230975A1 (es) 2005-05-01
NO339282B1 (no) 2016-11-21
ES2707714T3 (es) 2019-04-04
CZ300737B6 (cs) 2009-07-29
EP3059314A1 (en) 2016-08-24
HK1148776A1 (en) 2011-09-16
RU2303604C2 (ru) 2007-07-27
CY1109889T1 (el) 2012-01-25
FR10C0015I1 (cg-RX-API-DMAC7.html) 2010-04-16
TWI353358B (en) 2011-12-01
PT3059314T (pt) 2019-02-01
IL147992A (en) 2009-06-15
JP2009171966A (ja) 2009-08-06
KR20020047097A (ko) 2002-06-21
ECSP024210A (es) 2002-05-23
NO334808B1 (no) 2014-06-02
DK2230308T3 (da) 2013-05-06
DE60140738D1 (de) 2010-01-21
TR201900227T4 (tr) 2019-02-21
JP2007105043A (ja) 2007-04-26
PL212738B1 (pl) 2012-11-30
PT2308975T (pt) 2016-11-14
CY2019018I2 (el) 2020-05-29
JP2003535591A (ja) 2003-12-02
US20080269465A1 (en) 2008-10-30
EP2308975A1 (en) 2011-04-13
GB0128386D0 (en) 2002-01-16
HUS1700013I1 (hu) 2017-08-28
CA2707766C (en) 2013-05-21
AP2092A (en) 2010-02-28
NO2014026I1 (no) 2014-10-23
PT1287140E (pt) 2010-03-08
CY1118220T1 (el) 2017-06-28
CA2380298C (en) 2010-09-28
CZ2002837A3 (cs) 2002-05-15
IS2808B (is) 2012-09-15
DK2308975T3 (da) 2016-10-31
NL300982I1 (cg-RX-API-DMAC7.html) 2019-05-01
EP1287140A1 (en) 2003-03-05
ZA200200097B (en) 2003-01-06
BG66072B1 (bg) 2011-01-31
SI1287140T1 (sl) 2010-04-30
HUP1600016A2 (en) 2002-10-28
GB0013810D0 (en) 2000-07-26
US7402662B2 (en) 2008-07-22
ES2337763T3 (es) 2010-04-29
BRPI0106682B1 (pt) 2020-10-13
CA2707766A1 (en) 2001-12-13
EP2230308B1 (en) 2013-01-23
GB2366800B (en) 2005-01-19
JP4064812B2 (ja) 2008-03-19
LU91674I9 (cg-RX-API-DMAC7.html) 2019-01-03
NO20131316L (no) 2002-04-08
DK1287140T3 (da) 2010-04-19
EP2308975B1 (en) 2016-08-10
IS3016B (is) 2019-10-15
SI2230308T1 (sl) 2013-06-28
NO20020554L (no) 2002-04-08
NO341218B1 (no) 2017-09-11
PL218516B1 (pl) 2014-12-31
BRPI0106682B8 (pt) 2021-05-25
HUP0202346A3 (en) 2004-11-29
US20020151682A1 (en) 2002-10-17
US20060233800A1 (en) 2006-10-19
JP4476989B2 (ja) 2010-06-09
SK3152002A3 (en) 2002-07-02
HUP0202346A2 (en) 2002-10-28
CY1121173T1 (el) 2020-05-29
ES2600080T3 (es) 2017-02-07
SI2308975T1 (sl) 2016-11-30
PL399351A1 (pl) 2012-12-17
NO20160694A1 (no) 2002-04-08
AU783756B2 (en) 2005-12-01
CA2380298A1 (en) 2001-12-13
CY1114143T1 (el) 2016-07-27
IS6217A (is) 2002-01-03
OA12282A (en) 2006-05-11
WO2001094585A1 (en) 2001-12-13
LT2308975T (lt) 2016-11-10
IL195085A0 (en) 2009-08-03
NO2014026I2 (no) 2018-02-14
FR10C0015I2 (fr) 2011-12-30
HUP1600483A2 (cg-RX-API-DMAC7.html) 2002-10-28
TW200817430A (en) 2008-04-16
ES2230975B2 (es) 2007-04-16
US7186820B2 (en) 2007-03-06
NL300982I9 (nl) 2019-05-06
SK288343B6 (sk) 2016-04-01
CN1383450A (zh) 2002-12-04
ATE451460T1 (de) 2009-12-15
CY2010011I2 (el) 2012-01-25
NZ516596A (en) 2004-07-30
DK3059314T3 (en) 2019-02-18
GB2366800A (en) 2002-03-20
PT2230308E (pt) 2013-05-03
MY136603A (en) 2008-10-31
HU230553B1 (hu) 2016-11-28
CY2019018I1 (el) 2020-05-29
EP1287140B1 (en) 2009-12-09
HK1051385A1 (en) 2003-08-01
DE10192353T1 (de) 2003-05-22
AP2002002690A0 (en) 2002-12-31
LU91674I2 (fr) 2010-05-31
HU230561B1 (hu) 2016-12-28
CN1289671C (zh) 2006-12-13
JP5185143B2 (ja) 2013-04-17

Similar Documents

Publication Publication Date Title
AR033978A1 (es) Molecula de anticuerpo con especificidad para factor de necrosis tumoral alfa humano y usos de las mismas
CY1123400T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
DE60237778D1 (de) Antikörper gegen kdr, deren herstellung und verwendungen
EA200800953A1 (ru) Человеческие моноклональные антитела к cd70
CY1112055T1 (el) Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα
AR006250A1 (es) Compuestos y metodos para la inmunoterapia e inmunodiagnostico del cancer prostatico
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
LTPA2017044I1 (lt) Antikūnai, specifiški žmogaus CD22, ir jų terapinis bei diagnostinis panaudojimas
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
EA201100694A1 (ru) Антитело к cd38 человека и его применение
CY1112993T1 (el) Παραγοντες ειδικης δεσμευσης της αγγειοποιητινης-2 και της αγγειοποιητινης-1
AR038568A1 (es) Anticuerpos anti-a beta y su uso
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
AR047729A1 (es) Anticuerpos terapeuticos que se unen a la apolipoproteina e (apoe)
CL2004000859A1 (es) Anticuerpos capaces de unirse al factor tisular humano, sin que inhiba la coagulacion sanguinea, secuencias de nucleotidos que lo codifican, vector y celula que los produce; composicion farmaceutica y kit que los contienen; y sus usos para tratar el
LU92710I2 (fr) Ramucirumab et ses dérivés pharmaceutiquement acceptables (cyramza)
CY1108387T1 (el) Ανταγωνιστες ανασυνδυασμενης il-18 χρησιμοι στη θεραπεια παθησεων που εμφανιζονται με διαμεσολαβηση της il-18
CY1111622T1 (el) Ανθρωποποιημενοι ανταγωνιστες anti-cmet
EE200700052A (et) Antikeha he v?i mitme apo-lipoproteiin B fragmendi vastu
ATE526037T1 (de) Verfahren zum abtöten von tumorzellen mittels targeting von auf apoptotischen tumorzellen exponierten internen antigenen
ES2625823T3 (es) Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo
PE20050962A1 (es) Anticuerpos completamente humanos contra 4-1bb humano
EA200601219A1 (ru) Новые конденсированные пирролокарбазолы
AR124289A1 (es) Composiciones de agentes de unión a antígenos de guanilato ciclasa c (gcc) y métodos de uso de estos
EA200801174A1 (ru) Антитела-миметики glp-2, полипептиды, композиции, способы и применения

Legal Events

Date Code Title Description
FG Grant, registration